Rossana Scrivo

Publications

Title Published on Year
Treating psoriatic arthritis in the early phase: proposal for a shared dermatological and rheumatological therapeutic intervention with biologics and targets synthetic disease-modifying immunosuppressive drugs ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY 2025
Adalimumab in the management of psoriasis and psoriatic arthritis. results from a Delphi investigation RHEUMATOLOGY AND IMMUNOLOGY RESEARCH 2024
Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort REUMATISMO 2024
Assessment of Patient-Physician Interactions in Psoriatic Arthritis: National Results of the ASSIST Study RHEUMATOLOGY AND THERAPY 2024
PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors. REUMATISMO 2024
Diagnosing psoriatic arthritis in the early phase: what factors should dermatologists consider for an appropriate referral of patients with psoriasis to rheumatologists ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY 2024
Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2023
Patient-defined flares and disease activity worsening in 222 patients with psoriatic arthritis from 14 countries JOINT BONE SPINE 2023
ERAP1 and ERAP2 Haplotypes Influence Suboptimal HLA-B*27:05-Restricted Anti-Viral CD8+ T Cell Responses Cross-Reactive to Self-Epitopes INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2023
Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study RMD OPEN 2023
Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies REUMATISMO 2023
Editorial. drug survival. treatment of rheumatic diseases in the biologic era FRONTIERS IN MEDICINE 2022
Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries RMD OPEN 2022
The Conundrum of Psoriatic Arthritis: a Pathogenetic and Clinical Pattern at the Midpoint of Autoinflammation and Autoimmunity CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY 2022
Are interferon-gamma release assays reliable to detect tuberculosis infection in patients with rheumatoid arthritis treated with Janus kinase inhibitors? PLOS ONE 2022
The Conundrum of Psoriatic Arthritis: a Pathogenetic and Clinical Pattern at the Midpoint of Autoinflammation and Autoimmunity CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY 2022
Secukinumab Treatment in Patients with Spondyloarthritis and Concomitant Demyelinating Disease: Rationale of IL-17 Inhibition and Clinical Outcome. ARCHIVES OF CLINICAL AND MEDICAL CASE REPORTS 2022
Ovarian reserve in patients with spondyloarthritis: impact of biological disease-modifying anti-rheumatic drugs on fertility status CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2022
Ovarian reserve in patients with spondyloarthritis. impact of biological disease-modifying anti-rheumatic drugs on fertility status CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2022
The role of musculoskeletal ultrasound in predicting the response to JAK inhibitors. results from a monocentric cohort CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2022

ERC

  • LS6_4

KET

  • Life-science technologies & biotechnologies

Interessi di ricerca

Keywords

adaptive immune responses
polymyalgia rheumatica
rheumatoid arthritis
Spondyloarthritis
biologic agents

Progetti di Ricerca

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma